Mitochondrial Dysfunction in Parkinson's Disease: A Contribution to Cognitive Impairment?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 9

PMID 39519043

Authors

Antonella Scorziello

Rossana Sirabella

Maria Jose Sisalli

Michele Tufano

Lucia Giaccio

Elena DApolito

Lorenzo Castellano

Lucio Annunziato

Affiliations

Soon will be listed here.

Abstract

Among the non-motor symptoms associated with Parkinson's disease (PD), cognitive impairment is one of the most common and disabling. It can occur either early or late during the disease, and it is heterogeneous in terms of its clinical manifestations, such as Subjective Cognitive Dysfunction (SCD), Mild Cognitive Impairment (MCI), and Parkinson's Disease Dementia (PDD). The aim of the present review is to delve deeper into the molecular mechanisms underlying cognitive decline in PD. This is extremely important to delineate the guidelines for the differential diagnosis and prognosis of the dysfunction, to identify the molecular and neuronal mechanisms involved, and to plan therapeutic strategies that can halt cognitive impairment progression. Specifically, the present review will discuss the pathogenetic mechanisms involved in the progression of cognitive impairment in PD, with attention to mitochondria and their contribution to synaptic dysfunction and neuronal deterioration in the brain regions responsible for non-motor manifestations of the disease.

References

Robotta M, Gerding H, Vogel A, Hauser K, Schildknecht S, Karreman C . Alpha-synuclein binds to the inner membrane of mitochondria in an α-helical conformation. Chembiochem. 2014; 15(17):2499-502. DOI: 10.1002/cbic.201402281. View

Herrera M, Champarini L, Basmadjian O, Bellini M, Herenu C . IGF-1 gene therapy prevents spatial memory deficits and modulates dopaminergic neurodegeneration and inflammation in a parkinsonism model. Brain Behav Immun. 2024; 119:851-866. DOI: 10.1016/j.bbi.2024.05.013. View

Esteban-Martinez L, Sierra-Filardi E, Boya P . Mitophagy, metabolism, and cell fate. Mol Cell Oncol. 2017; 4(5):e1353854. PMC: 5644481. DOI: 10.1080/23723556.2017.1353854. View

Blandini F, Armentero M, Martignoni E . The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord. 2008; 14 Suppl 2:S124-9. DOI: 10.1016/j.parkreldis.2008.04.015. View

Shiba M, Bower J, Maraganore D, McDonnell S, Peterson B, Ahlskog J . Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15(4):669-77. DOI: 10.1002/1531-8257(200007)15:4<669::aid-mds1011>3.0.co;2-5. View

Tresse E, Marturia-Navarro J, Sew W, Cisquella-Serra M, Jaberi E, Riera-Ponsati L . Mitochondrial DNA damage triggers spread of Parkinson's disease-like pathology. Mol Psychiatry. 2023; 28(11):4902-4914. PMC: 10914608. DOI: 10.1038/s41380-023-02251-4. View

Goldman J, Sieg E . Cognitive Impairment and Dementia in Parkinson Disease. Clin Geriatr Med. 2020; 36(2):365-377. DOI: 10.1016/j.cger.2020.01.001. View

Theilmann R, Reed J, Song D, Huang M, Lee R, Litvan I . White-matter changes correlate with cognitive functioning in Parkinson's disease. Front Neurol. 2013; 4:37. PMC: 3624087. DOI: 10.3389/fneur.2013.00037. View

Emre M . Dementia associated with Parkinson's disease. Lancet Neurol. 2003; 2(4):229-37. DOI: 10.1016/s1474-4422(03)00351-x. View

10.

Weintraub D, Aarsland D, Chaudhuri K, Dobkin R, Leentjens A, Rodriguez-Violante M . The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol. 2021; 21(1):89-102. PMC: 8800169. DOI: 10.1016/S1474-4422(21)00330-6. View

11.

Lautenschlager J, Stephens A, Fusco G, Strohl F, Curry N, Zacharopoulou M . C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018; 9(1):712. PMC: 5818535. DOI: 10.1038/s41467-018-03111-4. View

12.

Poletti M, Vergallo A, Ulivi M, Sonnoli A, Bonuccelli U . Affective theory of mind in patients with Parkinson's disease. Psychiatry Clin Neurosci. 2013; 67(4):273-6. DOI: 10.1111/pcn.12045. View

13.

Aman Y, Ryan B, Torsetnes S, Knapskog A, Watne L, McEwan W . Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases. Int Rev Neurobiol. 2020; 155:169-202. DOI: 10.1016/bs.irn.2020.02.008. View

14.

Hayes M . Parkinson's Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807. DOI: 10.1016/j.amjmed.2019.03.001. View

15.

Przedborski S, Vila M . The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2003; 991:189-98. View

16.

Burton E, McKeith I, Burn D, Williams E, OBrien J . Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004; 127(Pt 4):791-800. DOI: 10.1093/brain/awh088. View

17.

Huang J, Yuan X, Chen L, Hu B, Jiang L, Shi T . Subjective cognitive decline in patients with Parkinson's disease: an updated review. Front Aging Neurosci. 2023; 15:1117068. PMC: 10251438. DOI: 10.3389/fnagi.2023.1117068. View

18.

Giordano N, Iemolo A, Mancini M, Cacace F, De Risi M, Latagliata E . Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease. Brain. 2017; 141(2):505-520. DOI: 10.1093/brain/awx351. View

19.

Roca M, Torralva T, Gleichgerrcht E, Chade A, Gomez Arevalo G, Gershanik O . Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cogn Behav Neurol. 2010; 23(3):152-8. DOI: 10.1097/WNN.0b013e3181e078de. View

20.

Johnson J, Mercado-Ayon E, Mercado-Ayon Y, Dong Y, Halawani S, Ngaba L . Mitochondrial dysfunction in the development and progression of neurodegenerative diseases. Arch Biochem Biophys. 2020; 702:108698. DOI: 10.1016/j.abb.2020.108698. View